Literature DB >> 8098074

Endogenous tissue-type plasminogen activator and risk of myocardial infarction.

P M Ridker1, D E Vaughan, M J Stampfer, J E Manson, C H Hennekens.   

Abstract

Endogenous tissue-type plasminogen activator (tPA) has been hypothesised to be a marker of baseline fibrinolytic capacity. We therefore tested whether tPA antigen is associated with the occurrence of future myocardial infarction (MI) among apparently healthy individuals. tPA antigen concentrations were measured at baseline in plasma samples from 231 apparently healthy men from the Physicians' Health Study cohort who later developed MI, and in an equal number of controls matched for age and smoking habit who remained free of reported cardiovascular disease during a follow-up of 60.2 months. In crude matched-pair analyses, baseline concentrations of tPA antigen were higher in cases than controls (p = 0.03) and strongly associated with risk of future MI. Specifically, the relative risks of developing a first MI from lowest (referent) to highest quintiles of tPA antigen were 1.00, 1.27, 1.75, 1.88, and 2.81 (p for trend 0.0008, 95% CI for the relative risk in the fifth as compared with first quintile 1.47 to 5.37, p = 0.002). Analyses which adjusted for risk factors that affect progression of atherosclerosis, particularly HDL-cholesterol, abolished the statistical significance of this association, a finding which suggests that elevations of tPA antigen are a result rather than a cause of atherosclerotic coronary disease. These prospective data suggest that endogenous tPA concentrations increase as a consequence of important preclinical atherosclerosis and therefore may be a marker for risk of future MI.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098074     DOI: 10.1016/0140-6736(93)90998-v

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  57 in total

Review 1.  Pathogenesis and pathology of coronary heart disease syndromes.

Authors:  P M Ridker; E M Antman
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

2.  Evaluation of overall fibrinolytic activity in patients with coronary artery ectasia: global fibrinolytic capacity.

Authors:  Abdullah Dogan; Bahattin Tunc; Oktay Ergene; Mehmet Ozaydin; Cem Nazli; Ahmet Altinbas; Omer Gedikli
Journal:  Int J Cardiovasc Imaging       Date:  2003-12       Impact factor: 2.357

3.  Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors.

Authors:  E B Rimm; P Williams; K Fosher; M Criqui; M J Stampfer
Journal:  BMJ       Date:  1999-12-11

Review 4.  Endothelial dysfunction in HIV infection.

Authors:  Bruno R Cotter
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

5.  Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels.

Authors:  Folkert W Asselbergs; Scott M Williams; Patricia R Hebert; Christopher S Coffey; Hans L Hillege; Gerjan Navis; Douglas E Vaughan; Wiek H van Gilst; Jason H Moore
Journal:  Genomics       Date:  2007-01-05       Impact factor: 5.736

Review 6.  Biomarkers and HIV-associated cardiovascular disease.

Authors:  Jason V Baker; Daniel Duprez
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

Review 7.  Angiotensin converting enzyme inhibitors--do they have an anti-ischemic action?

Authors:  J D Rutherford
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

8.  Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations?

Authors:  Eleni Hatzinikolaou-Kotsakou; Zarifis Kartasis; Dimitrios Tziakas; Athanasios Hotidis; Dimitrios Stakos; Konstantinos Tsatalas; Georgios Bourikas; Maria E Kotsakou; Dimitrios I Hatseras
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

9.  Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population.

Authors:  J A Schoenhard; F W Asselbergs; K A Poku; S A Stocki; S Gordon; D E Vaughan; N J Brown; J H Moore; Scott M Williams
Journal:  Hum Genet       Date:  2008-10-25       Impact factor: 4.132

10.  Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases.

Authors:  F O Akenami; V Sirén; M Koskiniemi; M A Siimes; H Teräväinen; A Vaheri
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.